TY - JOUR
T1 - Treatment of systemic fungal infections
T2 - Recent progress and current problems
AU - Walsh, T. J.
AU - Pizzo, A.
PY - 1988/8/1
Y1 - 1988/8/1
N2 - Systemic mycoses continue to emerge as life-threatening infections. Considerable progress in treating these infections is being achieved through better application of established available antifungal agents (amphotericin B, flucytosine, miconazole and ketoconazole), and through development of promising investigational agents (fluconazole, itraconazole). Systemic fungal infections, however, continue to present major problems, including clinical resistance, microbiological resistance, emergence of new pathogens, and involvement of more immunocompromised patients. The purpose of this paper, therefore, is to review the recent progress and current problems in treatment of systemic fungal infections.
AB - Systemic mycoses continue to emerge as life-threatening infections. Considerable progress in treating these infections is being achieved through better application of established available antifungal agents (amphotericin B, flucytosine, miconazole and ketoconazole), and through development of promising investigational agents (fluconazole, itraconazole). Systemic fungal infections, however, continue to present major problems, including clinical resistance, microbiological resistance, emergence of new pathogens, and involvement of more immunocompromised patients. The purpose of this paper, therefore, is to review the recent progress and current problems in treatment of systemic fungal infections.
UR - http://www.scopus.com/inward/record.url?scp=0023752762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023752762&partnerID=8YFLogxK
U2 - 10.1007/BF01962595
DO - 10.1007/BF01962595
M3 - Review article
C2 - 2846299
AN - SCOPUS:0023752762
SN - 0934-9723
VL - 7
SP - 460
EP - 475
JO - European Journal of Clinical Microbiology & Infectious Diseases
JF - European Journal of Clinical Microbiology & Infectious Diseases
IS - 4
ER -